240 related articles for article (PubMed ID: 15753391)
21. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
Hu B; Gilkes DM; Chen J
Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
[TBL] [Abstract][Full Text] [Related]
22. Novel roles for p53 in the genesis and targeting of tetraploid cancer cells.
Davaadelger B; Shen H; Maki CG
PLoS One; 2014; 9(11):e110844. PubMed ID: 25380055
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
[TBL] [Abstract][Full Text] [Related]
24. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.
Tovar C; Rosinski J; Filipovic Z; Higgins B; Kolinsky K; Hilton H; Zhao X; Vu BT; Qing W; Packman K; Myklebost O; Heimbrook DC; Vassilev LT
Proc Natl Acad Sci U S A; 2006 Feb; 103(6):1888-93. PubMed ID: 16443686
[TBL] [Abstract][Full Text] [Related]
25. 5-Fluorouracil interferes with paclitaxel cytotoxicity against human solid tumor cells.
Johnson KR; Wang L; Miller MC; Willingham MC; Fan W
Clin Cancer Res; 1997 Oct; 3(10):1739-45. PubMed ID: 9815558
[TBL] [Abstract][Full Text] [Related]
26. Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe.
Tse AN; Schwartz GK
Cancer Res; 2004 Sep; 64(18):6635-44. PubMed ID: 15374978
[TBL] [Abstract][Full Text] [Related]
27. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
Wang H; Nan L; Yu D; Agrawal S; Zhang R
Clin Cancer Res; 2001 Nov; 7(11):3613-24. PubMed ID: 11705884
[TBL] [Abstract][Full Text] [Related]
28. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells.
Coll-Mulet L; Iglesias-Serret D; Santidrián AF; Cosialls AM; de Frias M; Castaño E; Campàs C; Barragán M; de Sevilla AF; Domingo A; Vassilev LT; Pons G; Gil J
Blood; 2006 May; 107(10):4109-14. PubMed ID: 16439685
[TBL] [Abstract][Full Text] [Related]
29. First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models.
Pairawan S; Zhao M; Yuca E; Annis A; Evans K; Sutton D; Carvajal L; Ren JG; Santiago S; Guerlavais V; Akcakanat A; Tapia C; Yang F; Bose PSC; Zheng X; Dumbrava EI; Aivado M; Meric-Bernstam F
Breast Cancer Res; 2021 Mar; 23(1):29. PubMed ID: 33663585
[TBL] [Abstract][Full Text] [Related]
30. Selenomethionine induces p53 mediated cell cycle arrest and apoptosis in human colon cancer cells.
Goel A; Fuerst F; Hotchkiss E; Boland CR
Cancer Biol Ther; 2006 May; 5(5):529-35. PubMed ID: 16627976
[TBL] [Abstract][Full Text] [Related]
31. Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway.
Woods CM; Zhu J; McQueney PA; Bollag D; Lazarides E
Mol Med; 1995 Jul; 1(5):506-26. PubMed ID: 8529117
[TBL] [Abstract][Full Text] [Related]
32. Enhanced cytotoxicity of prenylated chalcone against tumour cells via disruption of the p53-MDM2 interaction.
Leão M; Soares J; Gomes S; Raimundo L; Ramos H; Bessa C; Queiroz G; Domingos S; Pinto M; Inga A; Cidade H; Saraiva L
Life Sci; 2015 Dec; 142():60-5. PubMed ID: 26475964
[TBL] [Abstract][Full Text] [Related]
33. Activation of p53-dependent apoptosis by acute ablation of glycogen synthase kinase-3beta in colorectal cancer cells.
Ghosh JC; Altieri DC
Clin Cancer Res; 2005 Jun; 11(12):4580-8. PubMed ID: 15958644
[TBL] [Abstract][Full Text] [Related]
34. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
Wang H; Yu D; Agrawal S; Zhang R
Prostate; 2003 Feb; 54(3):194-205. PubMed ID: 12518324
[TBL] [Abstract][Full Text] [Related]
35. Mdm2 ligase dead mutants did not act in a dominant negative manner to re-activate p53, but promoted tumor cell growth.
Swaroop M; Sun Y
Anticancer Res; 2003; 23(4):3167-74. PubMed ID: 12926050
[TBL] [Abstract][Full Text] [Related]
36. Pharmacologic p53 activation blocks cell cycle progression but fails to induce senescence in epithelial cancer cells.
Huang B; Deo D; Xia M; Vassilev LT
Mol Cancer Res; 2009 Sep; 7(9):1497-509. PubMed ID: 19737973
[TBL] [Abstract][Full Text] [Related]
37. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
Toledo F; Wahl GM
Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
[TBL] [Abstract][Full Text] [Related]
38. Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture.
Apontes P; Leontieva OV; Demidenko ZN; Li F; Blagosklonny MV
Oncotarget; 2011 Mar; 2(3):222-33. PubMed ID: 21447859
[TBL] [Abstract][Full Text] [Related]
39. Absence of p53-mediated G1 arrest with induction of MDM2 in sterigmatocystin-treated cells.
Xie TX; Misumi J; Aoki K; Zhao WY; Liu SY
Int J Oncol; 2000 Oct; 17(4):737-42. PubMed ID: 10995885
[TBL] [Abstract][Full Text] [Related]
40. Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding site.
Do TN; Rosal RV; Drew L; Raffo AJ; Michl J; Pincus MR; Friedman FK; Petrylak DP; Cassai N; Szmulewicz J; Sidhu G; Fine RL; Brandt-Rauf PW
Oncogene; 2003 Mar; 22(10):1431-44. PubMed ID: 12629507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
